Biocross is pleased to present at the 2016 Alzheimer’s Association International Conference® (AAIC®) in Toronto its work on the influence of APOE ε4 carrier status on the metabolomic profile of AD patients versus cognitively normal controls. The AAIC® is the world’s largest forum for the dementia research community.
Biocross has appointed Matthew Mittino as its new CEO. Biocross is currently developing several projects centered on the diagnosis of Alzheimer’s disease and the identification of populations at risk of developing the disease.
Biocross presents a fast and cost-effective method for apolipoprotein E isotyping for patient stratification in clinical trials
Biocross presents a fast and cost-effective method for apolipoprotein E isotyping as an alternative to APOE genotyping for patient stratification in clinical trials at the 2015 Clinical Trials for Alzheimer’s disease (CTAD) meeting in November 2015.
Early diagnosis of this disease is one of the factors that would enable better treatment. This is a key focus of many of the biotechnology companies that have emerged in recent decades.
CTAD 2014 presentation of a blood-based 7-metabolite signature for the early diagnosis of Alzheimer´s disease.
Biocross S.L., an innovative developer of assays for risk assessment and prediction of AD, has announced that it will be presenting a poster at the Clinical Trials on Alzheimer’s disease Conference, CTAD 2014, Philadelphia, United States, November 20-22nd, discussing its blood-based 7-metabolite signature for the early diagnosis of Alzheimer’s disease.
The company recently completed a multicenter exploratory study in which seven Spanish hospitals participated, to identify markers of the disease. The study involved 306 patients.